Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01895400
Other study ID # AMC-2013-0165
Secondary ID 20130055275
Status Terminated
Phase Phase 3
First received July 5, 2013
Last updated February 14, 2016
Start date July 2013
Est. completion date December 2015

Study information

Verified date February 2016
Source Asan Medical Center
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Renexin is effective in the treatment of vestibular symptoms in patients with recurrent vestibulopathy.


Description:

Read more »
Read more »

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Renexin (cilostazol 100mg + gingko biloba extract 80 mg)
Take Renexin 1T bid po medication for 8 weeks
Placebo
Take placebo drug 1T bid po medication for 8 weeks

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul

Sponsors (3)

Lead Sponsor Collaborator
Jong Woo Chung Asan Medical Center, SK Chemicals Co.,Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary equilibrium score of dynamic posturography compared with pretreatment equilibrium score after 8 weeks of treatment No
Secondary dizziness handicap inventory compared with pretreatment DHI score at 4 weeks, 8 weeks after treatment No
Secondary visual analogue scale (VAS) of vertigo compared with pretreatment VAS score at 4 weeks, 8 weeks after treatment No
Secondary Questionnaire for Quality of life (SF36) compared with pretreatment SF36 score at 4 weeks, 8 weeks after treatment Yes
See also
  Status Clinical Trial Phase
Suspended NCT04026516 - CAVA: Dizziness Trial N/A